Consistent with our prior studies showing α2-6 sialylation-dependent EGFR activation in other cancer cell lines (25), ST6Gal-I OE in Suit2 cells increased the α2-6 sialylation and basal activation of EGFR, whereas ST6Gal-I KD in S2-013 and S2-LM7AA diminished EGFR sialylation and activation. The gene discussed is EGFR; the disease is cancer.